Pharmacy Pearls: GLP-1 Receptor Agonists and SGLT2 Inhibitors – Comparison of CV OutcomesJune 29th, 2020 | Pharmacy Pearls•Diabetes
This edition of Pharmacy Pearls compares the CV outcome study characteristics and results for both the glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium glucose cotransporter 2 (SGLT2) inhibitor classes of medications. It also summarizes key points in regard to the newer oral GLP-1 RA, Rybelsus®, as well as a listing of expanded indications for the SGLT2 inhibitor class of medications. As a reminder, the first line approach for the treatment of type 2 diabetes remains metformin + lifestyle. You can view AHP’s best practices for management of type 2 diabetes by clicking here.
As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.